当前位置:首页 - 行情中心 - 泓博医药(301230) - 财务分析 - 利润表

泓博医药

(301230)

  

流通市值:22.70亿  总市值:41.23亿
流通股本:7686.03万   总股本:1.40亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入169,429,129.41544,471,262.04391,402,290.83265,763,514.46
营业收入169,429,129.41544,471,262.04391,402,290.83265,763,514.46
二、营业总成本157,965,262.18553,727,749.83396,611,989.68264,855,371.94
营业成本121,329,610.64414,537,085.85298,418,994.94202,566,520.19
税金及附加738,073.611,764,306.011,254,150.81797,962.8
销售费用3,624,165.1313,898,744.719,644,308.836,844,243.12
管理费用23,146,216.5875,283,356.1649,076,054.6831,716,228.05
研发费用8,726,167.9947,260,968.8535,900,683.0822,818,570.81
财务费用401,028.23983,288.252,317,797.34111,846.97
其中:利息费用2,172,427.419,281,930.577,046,648.794,751,248.03
其中:利息收入459,725.363,131,004.312,635,926.161,823,420.7
加:公允价值变动收益1,771,230.164,971,768.043,999,617.46184,024.09
加:投资收益59,178.083,435,499.973,503,429.135,327,629.02
资产减值损失(新)-1,007,845.9649,767.332,282,890.762,692,049.53
信用减值损失(新)-1,782,650.81-1,293,577.94-1,315,054.1-1,401,287.23
其他收益615,660.335,126,046.593,172,132.722,787,493.21
营业利润平衡项目0000
四、营业利润11,119,439.093,633,016.26,433,317.1210,498,051.14
加:营业外收入1.44189,118.24156,953.35123,620
减:营业外支出59,654.59287,018.07125,083.3252,357.53
利润总额平衡项目0000
五、利润总额11,059,785.943,535,116.376,465,187.1510,569,313.61
减:所得税费用-914,087.88-13,548,038.46-8,778,418.7-5,407,177.55
六、净利润11,973,873.8217,083,154.8315,243,605.8515,976,491.16
持续经营净利润11,973,873.8217,083,154.8315,243,605.8515,976,491.16
归属于母公司股东的净利润11,973,873.8217,083,154.8315,243,605.8515,976,491.16
(一)基本每股收益0.090.120.110.11
(二)稀释每股收益0.090.120.110.11
八、其他综合收益-81,158.6964,923.15-4,824.99-51,900.47
归属于母公司股东的其他综合收益-81,158.6964,923.15-4,824.99-51,900.47
九、综合收益总额11,892,715.1317,148,077.9815,238,780.8615,924,590.69
归属于母公司股东的综合收益总额11,892,715.1317,148,077.9815,238,780.8615,924,590.69
公告日期2025-04-292025-04-242024-10-282024-08-28
审计意见(境内)标准无保留意见
TOP↑